Physician profile
Christopher W Larson
NPI 1467773952
$4,332.99
in general payments reported to CMS, 2019-2025
14 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $1,354 · 2021: $499 · 2022: $42.05 · 2023: $486 · 2024: $19.81 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,182.24 | 2019-2020 | |
| Medtronic, INC. | $1,033.81 | 2021-2025 | Resolute Onyx, Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Abiomed | $427.46 | 2019 | |
| Lemaitre Vascular, INC. | $155.25 | 2023 | Artegraft Vascular Graft |
| Cardiovascular Systems INC. | $111.53 | 2019 | |
| Teleflex LLC | $94.56 | 2025 | Guideliner, Orsiro Mission |
| Lilly USA, LLC | $92.62 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.32 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $45.44 | 2020 | |
| Biotronik INC. | $40.25 | 2025 | Pantera Leo, Orsiro Mission, Pk Papyrus |
| Acacia Pharma INC | $24.29 | 2021 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Chiesi USA, INC. | $16.22 | 2025 | Cleviprex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.